Clinical Trial Update: Bioequivalence Study of Etodolac Extended Release Tablets USP 600mg Under Fed Condition [Phase 1]

View source ↗

Summary

A Phase 1 bioequivalence study of Etodolac Extended Release Tablets USP 600 mg evaluated under fed conditions has completed, sponsored by IPCA Laboratories Ltd.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoarthritis
• Rheumatoid Arthritis

Drugs mentioned

• Etodolac Extended Release Tablets USP 600 mg (Etodolac)

Snippet

Sponsor: IPCA Laboratories Ltd. | Conditions: Fasting | Phase 1 | Status: COMPLETED